Risk factor
Poor trading liquidity
Profitability factor
Strong margins and returns
About
Innova Captab Limited, established in Panchkula, India, in 2005, operates as a comprehensive pharmaceutical enterprise. Its operations encompass the full spectrum of drug development, from research and development and manufacturing to distribution and marketing, serving both domestic and international markets. The company also extends Contract Development and Manufacturing Organization (CDMO) services to other pharmaceutical businesses within India. Furthermore, Innova Captab is actively involved in developing, producing, and supplying a diverse array of generic medications. These formulations address a broad range of therapeutic areas, including anti-infectives (such as cephalosporins and antivirals), gastrointestinal treatments (like proton pump inhibitors and antiemetics), pain and inflammation management (including NSAIDs and analgesics), respiratory and allergy relief, cardiovascular support, antidiabetics, various neurological and psychiatric therapies, and solutions for urological conditions, among numerous other specialized segments. These pharmaceutical offerings are provided in multiple forms, such as tablets, capsules, dry syrups, injectable powders, ointments, and liquid oral preparations. Innova Captab distributes its branded generic products through an extensive network of distributors and pharmacies, in addition to utilizing various online e-commerce pharmacy platforms.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair valu
Target Price
The average target price of INNOVACAP.NS is 1053 and suggests 6.61% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recom